Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 916560, 11 pages
http://dx.doi.org/10.1155/2012/916560
Review Article

Regenerative Therapies for Diabetic Microangiopathy

1Nephrology Division, Transplantation Research Center (TRC), Children’s Hospital, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
2DiSTeBA, Università del Salento, 73100 Lecce, Italy
3Sorgente Research, 20127 Milan, Italy
4Department of Biophysical and Medical Science, Higher Institute of Medical Technology, 1006 Tunis, Tunisia
5Department of Medicine, San Raffaele Scientific Institute, 20132 Milan, Italy
6Department of Obstetrics and Gynecology, University of Bologna, 40138 Bologna, Italy

Received 17 November 2011; Accepted 18 January 2012

Academic Editor: Paolo Madeddu

Copyright © 2012 Roberto Bassi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. King, R. E. Aubert, and W. H. Herman, “Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections,” Diabetes Care, vol. 21, no. 9, pp. 1414–1431, 1998. View at Google Scholar · View at Scopus
  2. N. Chaturvedi, “The burden of diabetes and its complications: trends and implications for intervention,” Diabetes Research and Clinical Practice, vol. 76, no. 3, pp. S3–S12, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. A. R. Pries, B. Reglin, and T. W. Secomb, “Remodeling of blood vessels: responses of diameter and wall thickness to hemodynamic and metabolic stimuli,” Hypertension, vol. 46, no. 4, pp. 725–731, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. A. M. Heagerty, C. Aalkjaer, S. J. Bund, N. Korsgaard, and M. J. Mulvany, “Small artery structure in hypertension: dual processes of remodeling and growth,” Hypertension, vol. 21, no. 4, pp. 391–397, 1993. View at Google Scholar · View at Scopus
  5. D. M. Nathan, P. A. Cleary, J. Y. C. Backlund et al., “Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes,” New England Journal of Medicine, vol. 353, no. 25, pp. 2643–2653, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. Goldin, J. A. Beckman, A. M. Schmidt, and M. A. Creager, “Advanced glycation end products: sparking the development of diabetic vascular injury,” Circulation, vol. 114, no. 6, pp. 597–605, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. Z. S. Galis and J. J. Khatri, “Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly,” Circulation Research, vol. 90, no. 3, pp. 251–262, 2002. View at Google Scholar · View at Scopus
  8. H. Shamoon, H. Duffy, N. Fleischer et al., “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar
  9. R. C. Ramsay, F. C. Goetz, D. E. R. Sutherland et al., “Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus,” New England Journal of Medicine, vol. 318, no. 4, pp. 208–214, 1988. View at Google Scholar · View at Scopus
  10. T. C. Lee, N. R. Barshes, C. A. O'Mahony et al., “The effect of pancreatic islet transplantation on progression of diabetic retinopathy and neuropathy,” Transplantation Proceedings, vol. 37, no. 5, pp. 2263–2265, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. Venturini, P. Fiorina, P. Maffi et al., “Early increase of retinal arterial and venous blood flow velocities at color doppler imaging in brittle type 1 diabetes after islet transplant alone,” Transplantation, vol. 81, no. 9, pp. 1274–1277, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. P. Fioretto, M. W. Steffes, D. E. R. Sutherland, F. C. Goetz, and M. Mauer, “Reversal of lesions of diabetic nephropathy after pancreas transplantation,” New England Journal of Medicine, vol. 339, no. 2, pp. 69–75, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. Fioretto, S. M. Mauer, R. W. Bilous, F. C. Goetz, D. E. R. Sutherland, and M. W. Steffes, “Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys,” The Lancet, vol. 342, no. 8881, pp. 1193–1196, 1993. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Fiorina, F. Folli, G. Zerbini et al., “Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants,” Journal of the American Society of Nephrology, vol. 14, no. 8, pp. 2150–2158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. W. R. Kennedy, X. Navarro, F. C. Goetz, D. E. R. Sutherland, and J. S. Najarian, “Effects of pancreatic transplantation on diabetic neuropathy,” New England Journal of Medicine, vol. 322, no. 15, pp. 1031–1037, 1990. View at Google Scholar · View at Scopus
  16. U. Del Carro, P. Fiorina, S. Amadio et al., “Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation: neurophysiological and skin biopsy longitudinal analysis,” Diabetes Care, vol. 30, no. 12, pp. 3063–3069, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. P. Fiorina, C. Gremizzi, P. Maffi et al., “Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients,” Diabetes Care, vol. 28, no. 6, pp. 1358–1365, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-1-receptor antagonist in type 2 diabetes mellitus,” New England Journal of Medicine, vol. 356, no. 15, pp. 1517–1526, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. R. P. Robertson, “Islet transplantation as a treatment for diabetes—a work in progress,” New England Journal of Medicine, vol. 350, no. 7, pp. 694–705, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. R. P. Robertson, D. E. R. Sutherland, D. M. Kendall, A. U. Teuscher, R. W. G. Gruessner, and A. Gruessner, “Metabolic characterization of long-term successful pancreas transplants in type I diabetes,” Journal of Investigative Medicine, vol. 44, no. 9, pp. 549–555, 1996. View at Google Scholar · View at Scopus
  21. N. Cheung, P. Mitchell, and T. Y. Wong, “Diabetic retinopathy,” The Lancet, vol. 376, no. 9735, pp. 124–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. Wang, R. Klein, S. E. Moss et al., “The influence of combined kidney-pancreas transplantation on the progression of diabetic retinopathy: a case series,” Ophthalmology, vol. 101, no. 6, pp. 1071–1076, 1994. View at Google Scholar · View at Scopus
  23. E. La Rocca, C. Gobbi, D. Ciurlino, V. Di Carlo, G. Pozza, and A. Secchi, “Improvement of glucose/insulin metabolism reduces hypertension in insulin-dependent diabetes melitis recipients of kidney-pancreas transplantation,” Transplantation, vol. 65, no. 3, pp. 390–393, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Fioretto, D. E. R. Sutherland, B. Najafian, and M. Mauer, “Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients,” Kidney International, vol. 69, no. 5, pp. 907–912, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. X. Navarro, W. R. Kennedy, R. B. Lowenson, and D. E. R. Sutherland, “Influence of pancreas transplantation on cardiorespiratory reflexes, nerve conduction, and mortality in diabetes mellitus,” Diabetes, vol. 39, no. 7, pp. 802–806, 1990. View at Google Scholar · View at Scopus
  26. G. Solders, R. Gunnarsson, A. Persson, H. Wilczek, G. Tyden, and C. G. Groth, “Effects of combined pancreatic and renal transplantation on diabetic neuropathy: a two-year follow-up study,” The Lancet, vol. 2, no. 8570, pp. 1232–1235, 1987. View at Google Scholar · View at Scopus
  27. S. Martinenghi, G. Comi, G. Galardi, V. Di Carlo, G. Pozza, and A. Secchi, “Amelioration of nerve conduction velocity following simultaneous kidney/pancreas transplantation is due to the glycaemic control provided by the pancreas,” Diabetologia, vol. 40, no. 9, pp. 1110–1112, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. J. W. Jukema, Y. F. C. Smets, J. W. Van Der Pijl et al., “Impact of simultaneous pancreas and kidney transplantation on progression of coronary atherosclerosis in patients with end-stage renal failure due to type 1 diabetes,” Diabetes Care, vol. 25, no. 5, pp. 906–911, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Mandrup-Poulsen, L. Pickersgill, and M. Y. Donath, “Blockade of interleukin 1 in type 1 diabetes mellitus,” Nature Reviews Endocrinology, vol. 6, no. 3, pp. 158–166, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. B. Goldfine, R. Silver, W. Aldhahi et al., “Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes,” Clinical and Translational Science, vol. 1, no. 1, pp. 36–43, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. A. Fleischman, S. E. Shoelson, R. Bernier, and A. B. Goldfine, “Salsalate improves glycemia and inflammatory parameters in obese young adults,” Diabetes Care, vol. 31, no. 2, pp. 289–294, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. J.-M. Fernández-Real, A. López-Bermejo, A.-B. Ropero et al., “Salicylates increase insulin secretion in healthy obese subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2523–2530, 2008. View at Publisher · View at Google Scholar · View at PubMed
  33. M. Chen and R. P. Robertson, “Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon,” Diabetes, vol. 27, no. 7, pp. 750–756, 1978. View at Google Scholar · View at Scopus
  34. A. B. Goldfine, V. Fonseca, K. A. Jablonski, L. Pyle, M. A. Staten, and S. E. Shoelson, “The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial,” Annals of Internal Medicine, vol. 152, no. 6, pp. 346–357, 2010. View at Google Scholar · View at Scopus
  35. J. F. Navarro, C. Mora, A. Rivero et al., “Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration,” American Journal of Kidney Diseases, vol. 33, no. 3, pp. 458–463, 1999. View at Google Scholar · View at Scopus
  36. M. Rodríguez-Morán and F. Guerrero-Romero, “Pentoxifylline is as effective as captopril in the reduction of microalbuminuria in non-hypertensive type 2 diabetic patients—a randomized, equivalent trial,” Clinical Nephrology, vol. 64, no. 2, pp. 91–97, 2005. View at Google Scholar · View at Scopus
  37. S. Haffner, M. Temprosa, J. Crandall et al., “Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance,” Diabetes, vol. 54, pp. 1566–1572, 2005. View at Google Scholar
  38. E. M. Balk, J. Lau, L. C. Goudas et al., “Effects of statins on nonlipid serum markers associated with cardiovascular sisease: a systematic review,” Annals of Internal Medicine, vol. 139, no. 8, pp. 670–682, 2003. View at Google Scholar · View at Scopus
  39. D. Koya and G. L. King, “Protein kinase C activation and the development of diabetic complications,” Diabetes, vol. 47, no. 6, pp. 859–866, 1998. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Geraldes and G. L. King, “Activation of protein kinase C isoforms and its impact on diabetic complications,” Circulation Research, vol. 106, no. 8, pp. 1319–1331, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. D. J. Kelly, Y. Zhang, C. Hepper et al., “Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension,” Diabetes, vol. 52, no. 2, pp. 512–518, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. H. Ishii, M. R. Jirousek, D. Koya et al., “Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor,” Science, vol. 272, no. 5262, pp. 728–731, 1996. View at Google Scholar · View at Scopus
  43. K. R. Tuttle, G. L. Bakris, R. D. Toto, J. B. McGill, K. Hu, and P. W. Anderson, “The effect of ruboxistaurin on nephropathy in type 2 diabetes,” Diabetes Care, vol. 28, no. 11, pp. 2686–2690, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. L. P. Aiello, “The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial,” Diabetes, vol. 54, no. 7, pp. 2188–2197, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. L. P. Aiello, M. D. Davis, A. Girach et al., “Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy,” Ophthalmology, vol. 113, pp. 2221–2230, 2006. View at Google Scholar
  46. A. I. Vinik, V. Bril, P. Kempler et al., “Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C β-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial,” Clinical Therapeutics, vol. 27, no. 8, pp. 1164–1180, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. A. I. Vinik, V. Bril, W. J. Litchy, K. L. Price, and E. J. Bastyr, “Sural sensory action potential identifies diabetic peripheral neuropathy response to therapy,” Muscle and Nerve, vol. 32, no. 5, pp. 619–625, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. C. M. Casellini, P. M. Barlow, A. L. Rice et al., “A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-β inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy,” Diabetes Care, vol. 30, no. 4, pp. 896–902, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. J. A. Beckman, A. B. Goldfine, M. B. Gordon, L. A. Garrett, and M. A. Creager, “Inhibition of protein kinase Cβ prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans,” Circulation Research, vol. 90, no. 1, pp. 107–111, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Giacco and M. Brownlee, “Oxidative stress and diabetic complications,” Circulation Research, vol. 107, no. 9, pp. 1058–1070, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. M. C. Thomas, J. W. Baynes, S. R. Thorpe, and M. E. Cooper, “The role of AGEs and AGE inhibitors in diabetic cardiovascular disease,” Current Drug Targets, vol. 6, no. 4, pp. 453–474, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. T. Soulis-Liparota, M. Cooper, D. Papazoglou, B. Clarke, and G. Jerums, “Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat,” Diabetes, vol. 40, no. 10, pp. 1328–1334, 1991. View at Google Scholar · View at Scopus
  53. R. G. Tilton, K. Chang, K. S. Hasan et al., “Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation,” Diabetes, vol. 42, no. 2, pp. 221–232, 1993. View at Google Scholar · View at Scopus
  54. T. P. Degenhardt, N. L. Alderson, D. D. Arrington et al., “Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat,” Kidney International, vol. 61, no. 3, pp. 939–950, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. D. Joshi, R. Gupta, A. Dubey et al., “TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes,” Journal of Cardiovascular Pharmacology, vol. 54, no. 1, pp. 72–81, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. C. Demiot, M. Tartas, B. Fromy, P. Abraham, J. L. Saumet, and D. Sigaudo-Roussel, “Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic neuropathy,” Diabetes, vol. 55, no. 5, pp. 1478–1483, 2006. View at Publisher · View at Google Scholar · View at Scopus
  57. S. J. Zieman, V. Melenovsky, L. Clattenburg et al., “Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension,” Journal of Hypertension, vol. 25, no. 3, pp. 577–583, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. D. A. Kass, E. P. Shapiro, M. Kawaguchi et al., “Improved arterial compliance by a novel advanced glycation end-product crosslink breaker,” Circulation, vol. 104, no. 13, pp. 1464–1470, 2001. View at Google Scholar · View at Scopus
  59. G. M. Comer and T. A. Ciulla, “Pharmacotherapy for diabetic retinopathy,” Current Opinion in Ophthalmology, vol. 15, no. 6, pp. 508–518, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. N. Shams and T. Ianchulev, “Role of vascular endothelial growth factor in ocular angiogenesis,” Ophthalmology Clinics of North America, vol. 19, no. 3, pp. 335–344, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. D. B. Mendel, A. D. Laird, B. D. Smolich et al., “Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent,” Anti-Cancer Drug Design, vol. 15, no. 1, pp. 29–41, 2000. View at Google Scholar · View at Scopus
  62. D. J. Kelly, D. Buck, A. J. Cox, Y. Zhang, and R. E. Gilbert, “Effects on protein kinase C-β inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy,” American Journal of Physiology, vol. 293, no. 2, pp. F565–F574, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. R. Francese and P. Fiorina, “Immunological and regenerative properties of cord blood stem cells,” Clinical Immunology, vol. 136, no. 3, pp. 309–322, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. C. P. McGuckin and N. Forraz, “Potential for access to embryonic-like cells from human umbilical cord blood,” Cell Proliferation, vol. 41, no. 1, pp. 31–40, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. K. Naruse, Y. Hamada, E. Nakashima et al., “Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy,” Diabetes, vol. 54, no. 6, pp. 1823–1828, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. M. F. Pittenger, A. M. Mackay, S. C. Beck et al., “Multilineage potential of adult human mesenchymal stem cells,” Science, vol. 284, no. 5411, pp. 143–147, 1999. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Sensebé and P. Bourin, “Mesenchymal stem cells for therapeutic purposes,” Transplantation, vol. 87, no. 9, pp. S49–53, 2009. View at Google Scholar · View at Scopus
  68. K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringdén, “HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells,” Experimental Hematology, vol. 31, no. 10, pp. 890–896, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. E. Lombardo and O. Delarosa, “Modulation of adult mesenchymal stem cells activity by toll-like receptors: implications on therapeutic potential,” Mediators of Inflammation, vol. 2010, Article ID 865601, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. A. Corcione, F. Benvenuto, E. Ferretti et al., “Human mesenchymal stem cells modulate B-cell functions,” Blood, vol. 107, no. 1, pp. 367–372, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. M. Krampera, S. Glennie, J. Dyson et al., “Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide,” Blood, vol. 101, no. 9, pp. 3722–3729, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. S. Glennie, I. Soeiro, P. J. Dyson, E. W. F. Lam, and F. Dazzi, “Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells,” Blood, vol. 105, no. 7, pp. 2821–2827, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. B. Puissant, C. Barreau, P. Bourin et al., “Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells,” British Journal of Haematology, vol. 129, no. 1, pp. 118–129, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. L. Cui, Y. Shuo, W. Liu, N. Li, W. Zhang, and Y. Cao, “Expanded adipose-derived stem cells suppress mixed lymphocyte reaction by secretion of prostaglandin E2,” Tissue Engineering, vol. 13, no. 6, pp. 1185–1195, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. O. Delarosa, E. Lombardo, A. Beraza et al., “Requirement of IFN-γ-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells,” Tissue Engineering A, vol. 15, no. 10, pp. 2795–2806, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. X. X. Jiang, Y. Zhang, B. Liu et al., “Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells,” Blood, vol. 105, no. 10, pp. 4120–4126, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. G. M. Spaggiari, H. Abdelrazik, F. Becchetti, and L. Moretta, “MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2,” Blood, vol. 113, no. 26, pp. 6576–6583, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. I. Rasmusson, O. Ringdén, B. Sundberg, and K. Le Blanc, “Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells,” Transplantation, vol. 76, no. 8, pp. 1208–1213, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. N. Zhang, J. Li, R. Luo, J. Jiang, and J. A. Wang, “Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy,” Experimental and Clinical Endocrinology and Diabetes, vol. 116, no. 2, pp. 104–111, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. Y. Wu, L. Chen, P. G. Scott, and E. E. Tredget, “Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis,” Stem Cells, vol. 25, no. 10, pp. 2648–2659, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. Z. Yang, K. Li, X. Yan, F. Dong, and C. Zhao, “Amelioration of diabetic retinopathy by engrafted human adipose-derived mesenchymal stem cells in streptozotocin diabetic rats,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 248, no. 10, pp. 1415–1422, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. T. Murohara, “Therapeutic vasculogenesis using human cord blood-derived endothelial progenitors,” Trends in Cardiovascular Medicine, vol. 11, no. 8, pp. 303–307, 2001. View at Publisher · View at Google Scholar · View at Scopus
  83. I. Ahrens, H. Domeij, D. Topcic et al., “Successful in vitro expansion and differentiation of cord blood derived CD34+ cells into early endothelial progenitor cells reveals highly differential gene expression,” PLoS ONE, vol. 6, no. 8, 2011. View at Publisher · View at Google Scholar · View at PubMed
  84. T. Asahara, T. Murohara, A. Sullivan et al., “Isolation of putative progenitor endothelial cells for angiogenesis,” Science, vol. 275, no. 5302, pp. 964–967, 1997. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Hristov, W. Erl, and P. C. Weber, “Endothelial progenitor cells: mobilization, differentiation, and homing,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 7, pp. 1185–1189, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. I. Arnaoutova, J. George, H. K. Kleinman, and G. Benton, “The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art,” Angiogenesis, vol. 12, no. 3, pp. 267–274, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. L. S. Barcelos, C. Duplaa, N. Kränkel et al., “Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling,” Circulation Research, vol. 104, no. 9, pp. 1095–1102, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. P. Fiorina, G. Pietramaggiori, S. S. Scherer et al., “The mobilization and effect of endogenous bone marrow progenitor cells in diabetic wound healing,” Cell Transplantation, vol. 19, no. 11, pp. 1369–1381, 2010. View at Publisher · View at Google Scholar · View at PubMed
  89. J. Asai, H. Takenaka, K. F. Kusano et al., “Topical sonic hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell-mediated microvascular remodeling,” Circulation, vol. 113, no. 20, pp. 2413–2424, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. J. O. Jeong, M. O. Kim, H. Kim et al., “Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy,” Circulation, vol. 119, no. 5, pp. 699–708, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. S. Ylä-Herttuala, T. T. Rissanen, I. Vajanto, and J. Hartikainen, “Vascular endothelial growth factors. Biology and current status of clinical applications in cardiovascular medicine,” Journal of the American College of Cardiology, vol. 49, no. 10, pp. 1015–1026, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. D. Schrijvers, “Role of red blood cells in pharmacokinetics of chemotherapeutic agents,” Clinical Pharmacokinetics, vol. 42, no. 9, pp. 779–791, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Kastrup, “Therapeutic angiogenesis in ischemic heart disease: gene or recombinant vascular growth factor protein therapy?” Current Gene Therapy, vol. 3, no. 3, pp. 197–206, 2003. View at Google Scholar · View at Scopus
  94. J. M. Isner, I. Baumgartner, G. Rauh et al., “Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results,” Journal of Vascular Surgery, vol. 28, no. 6, pp. 964–975, 1998. View at Google Scholar · View at Scopus
  95. J. M. Isner, A. Pieczek, R. Schainfeld et al., “Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb,” The Lancet, vol. 348, no. 9024, pp. 370–374, 1996. View at Publisher · View at Google Scholar · View at Scopus
  96. K. G. Shyu, H. Chang, B. W. Wang, and P. Kuan, “Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia,” American Journal of Medicine, vol. 114, no. 2, pp. 85–92, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. D. Simovic, J. M. Isner, A. H. Ropper, A. Pieczek, and D. H. Weinberg, “Improvement in chronic ischemic neuropathy after intramuscular phVEGF165 gene transfer in patients with critical limb ischemia,” Archives of Neurology, vol. 58, no. 5, pp. 761–768, 2001. View at Google Scholar · View at Scopus
  98. I. Kholová, S. Koota, N. Kaskenpää et al., “Adenovirus-mediated gene transfer of human vascular endothelial growth factor-D induces transient angiogenic effects in mouse hind limb muscle,” Human Gene Therapy, vol. 18, no. 3, pp. 232–244, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. S. Rajagopalan, M. Shah, A. Luciano, R. Crystal, and E. G. Nabel, “Adenovirus-mediated gene transfer of VEGF121 improves lower-extremity endothelial function and flow reserve,” Circulation, vol. 104, no. 7, pp. 753–755, 2001. View at Google Scholar · View at Scopus
  100. Y. H. Kusumanto, V. Van Weel, N. H. Mulder et al., “Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial,” Human Gene Therapy, vol. 17, no. 6, pp. 683–691, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. T. A. Khan, F. W. Sellke, and R. J. Laham, “Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia,” Gene Therapy, vol. 10, no. 4, pp. 285–291, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. A. Germani, C. Di Campli, G. Pompilio, P. Biglioli, and M. C. Capogrossi, “Regenerative therapy in peripheral artery disease,” Cardiovascular Therapeutics, vol. 27, no. 4, pp. 289–304, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. S. Nikol, I. Baumgartner, E. Van Belle et al., “Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia,” Molecular Therapy, vol. 16, no. 5, pp. 972–978, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. I. Baumgartner, N. Chronos, A. Comerota et al., “Local gene transfer and expression following intramuscular administration of FGF-1 plasmid DNA in patients with critical limb ischemia,” Molecular Therapy, vol. 17, no. 5, pp. 914–921, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. F. G. R. Fowkes and J. F. Price, “Gene therapy for critical limb ischaemia: the TAMARIS trial,” The Lancet, vol. 377, no. 9781, pp. 1894–1896, 2011. View at Publisher · View at Google Scholar
  106. P. Dell'Era, M. Belleri, H. Stabile, M. L. Massardi, D. Ribatti, and M. Presta, “Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells,” Oncogene, vol. 20, no. 21, pp. 2655–2663, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. A. Praidou, S. Androudi, P. Brazitikos, G. Karakiulakis, E. Papakonstantinou, and S. Dimitrakos, “Angiogenic growth factors and their inhibitors in diabetic retinopathy,” Current Diabetes Reviews, vol. 6, no. 5, pp. 304–312, 2010. View at Google Scholar
  108. R. Morishita, S. Nakamura, S. I. Hayashi et al., “Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy,” Hypertension, vol. 33, no. 6, pp. 1379–1384, 1999. View at Google Scholar · View at Scopus
  109. Y. Taniyama, R. Morishita, M. Aoki et al., “Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease,” Gene Therapy, vol. 8, no. 3, pp. 181–189, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. R. J. Powell, M. Simons, F. O. Mendelsohn et al., “Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia,” Circulation, vol. 118, no. 1, pp. 58–65, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. D. J. Ceradini, A. R. Kulkarni, M. J. Callaghan et al., “Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1,” Nature Medicine, vol. 10, no. 8, pp. 858–864, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. M. Bosch-Marce, H. Okuyama, J. B. Wesley et al., “Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia,” Circulation Research, vol. 101, no. 12, pp. 1310–1318, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. T. H. Patel, H. Kimura, C. R. Weiss, G. L. Semenza, and L. V. Hofmann, “Constitutively active HIF-1α improves perfusion and arterial remodeling in an endovascular model of limb ischemia,” Cardiovascular Research, vol. 68, no. 1, pp. 144–154, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. S. Rajagopalan, J. Olin, S. Deitcher et al., “Use of a constitutively active hypoxia-inducible factor-1α transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience,” Circulation, vol. 115, no. 10, pp. 1234–1243, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. M. Meloni, A. Caporali, G. Graiani et al., “Nerve growth factor promotes cardiac repair following myocardial infarction,” Circulation Research, vol. 106, no. 7, pp. 1275–1284, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. C. Emanueli, M. B. Salis, A. Pinna, G. Graiani, L. Manni, and P. Madeddu, “Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs,” Circulation, vol. 106, no. 17, pp. 2257–2262, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. N. Hansen-Algenstaedt, P. Algenstaedt, C. Schaefer et al., “Neural driven angiogenesis by overexpression of nerve growth factor,” Histochemistry and Cell Biology, vol. 125, no. 6, pp. 637–649, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. M. J. Park, H. J. Kwak, H. C. Lee et al., “Nerve growth factor induces endothelial cell invasion and cord formation by promoting matrix metalloproteinase-2 expression through the phosphatidylinositol 3-kinase/Akt signaling pathway and AP-2 transcription factor,” Journal of Biological Chemistry, vol. 282, no. 42, pp. 30485–30496, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  119. M. Meloni, B. Descamps, A. Caporali et al., “Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice,” Diabetes, vol. 61, no. 1, pp. 229–240, 2012. View at Publisher · View at Google Scholar · View at PubMed
  120. C. Emanueli and P. Madeddu, “Human tissue kallikrein: a new bullet for the treatment of ischemia,” Current Pharmaceutical Design, vol. 9, no. 7, pp. 589–597, 2003. View at Publisher · View at Google Scholar
  121. P. Porcu, C. Emanueli, M. Kapatsoris, J. Chao, L. Chao, and P. Madeddu, “Reversal of angiogenic growth factor upregulation by revascularization of lower limb ischemia,” Circulation, vol. 105, no. 1, pp. 67–72, 2002. View at Publisher · View at Google Scholar · View at Scopus
  122. R. S. Smith, L. Gao, L. Chao, and J. Chao, “Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia,” Biological Chemistry, vol. 389, no. 6, pp. 725–730, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. C. Emanueli, A. Zacheo, A. Minasi et al., “Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 11, pp. 2379–2385, 2000. View at Google Scholar
  124. C. Emanueli, M. B. Salis, A. Pinna et al., “Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer,” Circulation, vol. 106, no. 8, pp. 993–999, 2002. View at Publisher · View at Google Scholar · View at Scopus